I am a shareholder in APL Apollo Tubes and in Alkem? Can you tell me about the latest quarterly results announced by both the companies?

Let me talk about APL Apollo Tubes first. The company witnessed 62.9% growth in sales revenues for Q4FY22 at Rs4,080 crore. FY22 full year revenues were up 53.7% at Rs12,625 crore. APL Apollo Tubes reported 27% growth in sales volumes at 552K tonnes for Q4FY22 while for full year the sales volumes was up 7% at 1,755K tonnes. EBITDA per tonne for Q4 FY22 was up 2% at Rs4,823. For FY22, ROE was 28.8% while ROCE stood at a healthy 34.5%.

Let me now turn to the profit performance of APL Apollo Tubes. Net profits for Q4FY22 were up 36.73% at Rs163 crore and could have been still better but for input cost pressures. EBITDA for Q4FY22 was up 29% at Rs270 crore as interest cost fell 30% yoy on debt reduction program. Net margins were 3.99% in Q4FY22 quarter compared to 4.79% in Q4FY21. However, the NPM was higher compared to 3.70% in Q3FY22.

I will not turn to the second company held by you, the pharma major Alkem Ltd. Sales growth for the quarter was 13.31% at Rs2,484 crore. FY22 full year revenues were up 19.95% at Rs10,634 crore. While Alkem India sales were up 16.7% at Rs1,719 crore, global sales were up 7.3% at Rs741 crore. There was significant pricing pressures in the US markets resulting in subdued revenue growth overall, even as volumes remained robust

However, profits of Alkem fell sharply by -55.2% at Rs108 crore for Q4FY22. This was on account of significant pricing pressures in the US markets, as already stated. India growth was led by anti-infectives, vitamins and pain management verticals. Net margins stood at 4.33% in Q4FY22 quarter compared to 10.95% and 20.07% in Q3FY22. Incidentally, the EBITDA margins improved by 30 bps to 13.6%. R&D costs were a healthy 6.6% of revenues.